Trademark: PALISADE BIO 2164207
Word
PALISADE BIO
ID
2164207
Trademark Type
Word
Status
Protected: Registered/protected
Application Date
29 January 2021
Registration Date
29 January 2021
Renewal Date
29 January 2031
Owner(s)
Service
WRAYS PTY LTD
Goods and Services:
Class 5:
Pharmaceutical formulations and preparations to treat acute and chronic health conditions related to gastrointestinal, inflammatory, metabolic, endocrine, immunological, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, oncological, hepatological, respiratory, neurological, psychiatric, dermatological, and viral diseases and disorders; pharmaceutical compositions in liquid form, namely, liquid compositions containing protease inhibitors, to treat health conditions, diseases, and disorders related to the gastrointestinal tract, gastrointestinal permeability, the gastrointestinal epithelial barrier, gastrointestinal inflammation, the gastrointestinal immune system, the microbiome, and the gut-brain axis; pharmaceutical formulations and preparations to treat or prevent surgical complications and postsurgical complications; pharmaceutical formulations and preparations to treat or prevent shock, namely, acute shock, cardiogenic shock, septic shock, hemorrhagic shock, and shock associated with hypoperfusion; pharmaceutical formulations and preparations to treat or prevent gastrointestinal tract injuries, ileus, and adhesions; pharmaceutical formulations and preparations to treat or prevent multiorgan failure; pharmaceutical formulations and preparations to treat or prevent health conditions, diseases, and disorders related to intestinal permeability, the microbiome, and the gut-brain axis.
Pharmaceutical formulations and preparations to treat acute and chronic health conditions related to gastrointestinal, inflammatory, metabolic, endocrine, immunological, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, oncological, hepatological, respiratory, neurological, psychiatric, dermatological, and viral diseases and disorders; pharmaceutical compositions in liquid form, namely, liquid compositions containing protease inhibitors, to treat health conditions, diseases, and disorders related to the gastrointestinal tract, gastrointestinal permeability, the gastrointestinal epithelial barrier, gastrointestinal inflammation, the gastrointestinal immune system, the microbiome, and the gut-brain axis; pharmaceutical formulations and preparations to treat or prevent surgical complications and postsurgical complications; pharmaceutical formulations and preparations to treat or prevent shock, namely, acute shock, cardiogenic shock, septic shock, hemorrhagic shock, and shock associated with hypoperfusion; pharmaceutical formulations and preparations to treat or prevent gastrointestinal tract injuries, ileus, and adhesions; pharmaceutical formulations and preparations to treat or prevent multiorgan failure; pharmaceutical formulations and preparations to treat or prevent health conditions, diseases, and disorders related to intestinal permeability, the microbiome, and the gut-brain axis.